Trial Profile

Tyrosine-kinase Inhibitor TKI With or Without SBRT in Newly Diagnosed EGFRm Advanced Staged Lung Adenocarcinoma

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 07 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erlotinib (Primary) ; Gefitinib (Primary) ; Icotinib (Primary)
Indications Adenocarcinoma; Lung cancer; Non-small cell lung cancer
Focus Therapeutic Use
Acronyms Sindas

Most Recent Events

07 Feb 2022 New trial record
30 Jan 2022 Primary endpoint has been met. (Progression free survival)
30 Jan 2022 Interim Results published in the Journal of the National Cancer Institute

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com